An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Conditions: Multiple Sclerosis (MS) Interventions: Drug: Avonex (IFN β-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs) Sponsors: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Condition: COVID-19 Interventions: Drug: Interferon beta-1b; Drug: Clofazimine Sponsor: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials
An Open-label Trial on Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Condition: COVID-19 Interventions: Drug: Interferon beta-1b; Drug: Clofazimine Sponsor: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Condition: COVID-19 Interventions: Drug: Interferon beta-1b; Drug: Clofazimine Sponsor: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials
An Open-label Trial on Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Condition: COVID-19 Interventions: Drug: Interferon beta-1b; Drug: Clofazimine Sponsor: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial
This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services.Intervention and comparatorCOVID-19 confirmed patients will be randomly assigned to one of three groups, with 20 patients in each. The first group (Arm 1) will receive Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon- β 1a (Recigen), the second group (Arm 2) will be administered Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-β 1b (Ziferon), and the control group (Arm 3) will be treated by Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra).Main outcomesTime t...
Source: Trials - June 2, 2020 Category: Research Source Type: clinical trials
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
Condition: Multiple Sclerosis Intervention: Drug: Interferon-beta-1b (BETASERON, BAY 86-5046) Sponsor: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2020 Category: Research Source Type: clinical trials
